{"nctId":"NCT01737762","briefTitle":"Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2","startDateStruct":{"date":"2012-11"},"conditions":["Venous Leg Ulcers"],"count":155,"armGroups":[{"label":"HP802-247","type":"EXPERIMENTAL","interventionNames":["Biological: HP802-247"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Vehicle"]}],"interventions":[{"name":"HP802-247","otherNames":[]},{"name":"Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provide informed consent.\n* Age ≥ 18 years and of either sex.\n* Willing to comply with protocol instructions, including allowing all study assessments.\n* Have a venous leg ulcer (VLU) between the knee and ankle (at or above the malleolus), with a surface area \\>12 cm2 to ≤ 36 cm2\n* Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence.\n* Arterial supply adequacy confirmed\n* Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon, muscle, or bone.\n* Target ulcer duration ≥ 6 weeks but ≤ 104 weeks (24 months).\n* Acceptable state of health and nutrition\n\nExclusion Criteria:\n\n* History of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, amphotericin B.\n* Prior diagnosis of Systemic Lupus Erythematosus with elevated anti-DNA antibody titers, Buerger's disease (thromboangiitis obliterans), current diagnosis of vasculitis, or current diagnosis of claudication.\n* Therapy with another investigational agent within thirty (30) days of Screening, or during the study.\n* A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic).\n* Documented history of osteomyelitis at the target wound location within 6 months preceding the Screening Visit.\n* Refusal of or inability to tolerate compression therapy.\n* Therapy of the target ulcer with autologous skin graft, Apligraf™, or Dermagraft™ within 30 days preceding the Screening Visit.\n* History of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancers).\n* Any prior exposure to HP802-247 or its vehicle.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Wound Closure","description":"Compare HP802-247 plus compression therapy against Vehicle plus compression therapy for proportion of subjects with complete wound closure over the 16-week treatment period from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Time in Days to Closure","description":"Compare the efficacy of HP802-247 plus compression therapy against Vehicle plus compression therapy in achieving complete wound closure, based on time in days to closure over the 16-week treatment period from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.4","spread":"33.8"},{"groupId":"OG001","value":"87.1","spread":"42.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":77},"commonTop":["Skin ulcer","Cellulitis","Wound complication","Infected skin ulcer","Wound infecton"]}}}